GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Update

GT Biopharma, Inc. (NASDAQ:GTBP) was the recipient of a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 10,400 shares, an increase of 108.0% from the September 30th total of 5,000 shares. Currently, 0.5% of the company’s stock are short sold. Based on an average daily volume of 14,500 shares, the short-interest ratio is currently 0.7 days.

GT Biopharma Stock Up 3.3 %

GT Biopharma stock traded up $0.10 during trading on Friday, reaching $3.12. 44,103 shares of the company’s stock were exchanged, compared to its average volume of 433,232. The company’s 50-day moving average is $2.19 and its two-hundred day moving average is $2.82. GT Biopharma has a 52-week low of $1.92 and a 52-week high of $10.66.

GT Biopharma (NASDAQ:GTBP) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($2.24) earnings per share for the quarter.

Institutional Trading of GT Biopharma

A hedge fund recently bought a new stake in GT Biopharma stock. DekaBank Deutsche Girozentrale acquired a new stake in GT Biopharma, Inc. (NASDAQ:GTBP) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,093,645 shares of the company’s stock, valued at approximately $47,449,000. DekaBank Deutsche Girozentrale owned about 77.02% of GT Biopharma at the end of the most recent reporting period. 8.15% of the stock is owned by hedge funds and other institutional investors.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.